RU2016150096A3 - - Google Patents

Download PDF

Info

Publication number
RU2016150096A3
RU2016150096A3 RU2016150096A RU2016150096A RU2016150096A3 RU 2016150096 A3 RU2016150096 A3 RU 2016150096A3 RU 2016150096 A RU2016150096 A RU 2016150096A RU 2016150096 A RU2016150096 A RU 2016150096A RU 2016150096 A3 RU2016150096 A3 RU 2016150096A3
Authority
RU
Russia
Application number
RU2016150096A
Other versions
RU2016150096A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016150096A publication Critical patent/RU2016150096A/ru
Publication of RU2016150096A3 publication Critical patent/RU2016150096A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2016150096A 2014-05-29 2015-05-27 Белки слияния на основе ox40l и пути их применения RU2016150096A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462004555P 2014-05-29 2014-05-29
US62/004,555 2014-05-29
US201562111796P 2015-02-04 2015-02-04
US62/111,796 2015-02-04
PCT/US2015/032598 WO2015183902A1 (en) 2014-05-29 2015-05-27 Ox40l fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
RU2016150096A RU2016150096A (ru) 2018-07-02
RU2016150096A3 true RU2016150096A3 (ru) 2019-01-24

Family

ID=53540957

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016150096A RU2016150096A (ru) 2014-05-29 2015-05-27 Белки слияния на основе ox40l и пути их применения

Country Status (10)

Country Link
US (1) US9718870B2 (ru)
EP (1) EP3148573A4 (ru)
JP (1) JP6666267B2 (ru)
CN (1) CN106456734A (ru)
BR (1) BR112016027845A2 (ru)
GB (1) GB2532817A (ru)
MX (1) MX360295B (ru)
RU (1) RU2016150096A (ru)
TW (1) TW201623327A (ru)
WO (1) WO2015183902A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027845A2 (pt) * 2014-05-29 2017-10-31 Medimmune Llc proteínas de fusão de ox40l e usos das mesmas
CN113372434B (zh) 2014-11-14 2024-06-04 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体的抗原结合分子
ES2845727T3 (es) 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
US11536716B2 (en) * 2015-06-25 2022-12-27 Hoffmann-La Roche Inc. Cell based assay for determining antibody or ligand binding and function
KR20180033588A (ko) 2015-08-12 2018-04-03 메디뮨 리미티드 Ｇｉｔｒｌ 융합 단백질 및 그의 용도
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP6981973B2 (ja) 2015-10-01 2021-12-17 ヒート バイオロジクス，インコーポレイテッド Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US10331233B2 (en) * 2016-10-27 2019-06-25 Fluidity Technologies, Inc. Camera and sensor controls for remotely operated vehicles and virtual environments
US10331232B2 (en) * 2016-10-27 2019-06-25 Fluidity Technologies, Inc. Controller with situational awareness display
US11230610B2 (en) * 2016-12-09 2022-01-25 Seagen Inc. Bivalent antibodies masked by coiled coils
CA3047059A1 (en) * 2016-12-19 2018-06-28 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
CN110381974A (zh) 2017-02-27 2019-10-25 沙塔克实验室有限公司 基于csf1r的嵌合蛋白
CN118184797A (zh) 2017-02-27 2024-06-14 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
CN110381983B (zh) 2017-02-27 2024-07-09 沙塔克实验室有限公司 基于tigit和light的嵌合蛋白
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
MX2019012849A (es) * 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
CN109839509A (zh) * 2019-02-15 2019-06-04 浠思（上海）生物技术有限公司 利用ox40/ox40l的htrf结合分析实验技术筛选潜在激动剂的方法
US20230183366A1 (en) * 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
WO2022155526A2 (en) * 2021-01-15 2022-07-21 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Hybrid and truncated immune cell proteins
WO2023088437A1 (zh) * 2021-11-19 2023-05-25 南开大学 重组武装溶瘤病毒组合物及其在til过继治疗中的用途
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
EP1572936A2 (en) * 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
JP4958555B2 (ja) * 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
PT1877090E (pt) * 2005-05-06 2014-04-15 Providence Health System Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização
AU2013263717B2 (en) * 2005-05-06 2016-05-19 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007067682A2 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. In vivo cell surface engineering
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2819693A4 (en) * 2012-03-02 2015-10-28 Providence Health & Services Oregon ANTICANCER BITHERAPY BASED ON OX40 / IL-2 AGONIST
BR112016027845A2 (pt) * 2014-05-29 2017-10-31 Medimmune Llc proteínas de fusão de ox40l e usos das mesmas
US20190194654A1 (en) * 2014-10-24 2019-06-27 Astrazeneca Ab Combination

Also Published As

Publication number Publication date
TW201623327A (zh) 2016-07-01
CN106456734A (zh) 2017-02-22
RU2016150096A (ru) 2018-07-02
JP6666267B2 (ja) 2020-03-13
US9718870B2 (en) 2017-08-01
BR112016027845A2 (pt) 2017-10-31
WO2015183902A1 (en) 2015-12-03
JP2017519494A (ja) 2017-07-20
GB2532817A (en) 2016-06-01
EP3148573A1 (en) 2017-04-05
MX360295B (es) 2018-10-29
GB201509062D0 (en) 2015-07-08
US20160024176A1 (en) 2016-01-28
MX2016014647A (es) 2017-05-30
EP3148573A4 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
BR112016022637A2 (ru)
BR112016019084A2 (ru)
BR112016016536A2 (ru)
BR112016015519A2 (ru)
BR112016022298A2 (ru)
RU2016150096A3 (ru)
BR112016017429A2 (ru)
BR112016022014A2 (ru)
BR112016019575A2 (ru)
BR112016017337A2 (ru)
BR112016022164A2 (ru)
BR112016019573A2 (ru)
BR112016020096A2 (ru)
BR112016018468A2 (ru)
BR112016021745A2 (ru)
BR112016022284A2 (ru)
BR112016021768A2 (ru)
BR112016021941A2 (ru)
BR112016020587A2 (ru)
BR112016026451A2 (ru)
BR112016015642A2 (ru)
BR112016020335A2 (ru)
BR112016026370A2 (ru)
BR112016020595A2 (ru)
BR112016022141A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191009